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hypertensive drugs, such as calcium-channel 
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Dutasteride and Prostate Cancer
To the Editor: In the Reduction by Dutasteride 
of Prostate Cancer Events (REDUCE) trial, Andri-
ole et al. (April 1 issue)1 found that there was a 
reduction in low-grade prostate cancer among 
high-risk men after dutasteride treatment — sim-
ilar to the results with finasteride therapy among 
low-risk men in the Prostate Cancer Prevention 
Trial.2 However, there was a slightly increased 
risk of high-grade tumors in the dutasteride group 
at the end of the study. The authors speculate 
that this was caused by the more frequent early 
detection of low-grade tumors in the placebo 
group. Some of these might have progressed to 
higher grades if left untreated. But if so, wouldn’t 
this counterbalance the beneficial lower rate of 
biopsies for cause in the dutasteride group?
The end-of-study cumulative risk of prostate 
cancer among participants in the placebo group 
in both studies was extremely high (24 to 25%). 
With the use of data from the Surveillance, Epi-
demiology and End Results (SEER) program, one 
can calculate that participants in the Prostate 
Cancer Prevention Trial would have had a 7-year 
cumulative risk of only 6% if they had not par-
ticipated in the trial. Participants in the REDUCE 
trial would have had a 4-year cumulative risk of 
8 to 10% in the absence of protocol-driven 
 biopsies, on the basis of data from the Euro-
pean Randomized Study of Screening for Pros-
tate Cancer (Current Controlled Trials number, 
ISRCTN49127736).3 Thus, the protocol-directed 
interim and end-of-study biopsies make it impos-
sible to directly translate the results to public 
health or clinical practice.
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To the Editor: The long-expected results of the 
REDUCE trial show that among men 50 to 75 years 
of age who have prostate-specific antigen (PSA) 
levels of 2.5 to 10.0 ng per milliliter and who 
have previously undergone biopsies, the 5α-reduc-
tase inhibitor dutasteride significantly reduces 
the rate of positive biopsies by 23%. The 24.9% 
rate of positive biopsy results among men who 
underwent at least two biopsies is consistent with 
the expressed purpose of the organizers to study 
a population that had a relatively high risk of 
prostate cancer. Protocol-mandated biopsies were 
carried out at year 2 and year 4 during the study. 
This procedure is in line with clinical practice.
Unfortunately, the authors do not address the 
possibility of avoiding at least some of the 82.8% 
of negative biopsies. Although the difference in 
positive biopsies must be considered a very pre-
liminary end point, the possibility that the use 
of dutasteride avoids unnecessary biopsies must 
be explored. It has great relevance in a clinical 
environment, in which the overdiagnosis and 
overtreatment of prostate cancer are considered 
to be a major health care problem.
Fritz H. Schröder, M.D. 
Monique J. Roobol, Ph.D.
Erasmus Medical Center 
Rotterdam, the Netherlands 
secr.schroder@erasmusmc.nl
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on December 6, 2012. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;8 nejm.org august 19, 2010794
No potential conflict of interest relevant to this letter was re-
ported.
To the Editor: In the editorial accompanying 
the article by Andriole et al., Walsh1 convincingly 
disproves the conclusion of the REDUCE study, 
stating that dutasteride does not prevent prostate 
cancer but merely shrinks tumors. According to 
Walsh, this holds true for finasteride as well. 
However, this view cannot provide a post hoc jus-
tification for the use of placebo instead of finas-
teride as a control in the trial of dutasteride ther-
apy. The REDUCE trial was based on the alleged 
evidence that made finasteride the current stan-
dard of treatment — that is, the reported 25% 
reduction in the risk of prostate cancer2 — and 
aimed at showing that dutasteride did as well 
and possibly better by avoiding the 27% increase 
with finasteride in less well differentiated tumors 
that are more likely to be lethal. These expecta-
tions were possibly fueled by the fact that, unlike 
finasteride, dutasteride inhibits both type 1 and 
type 2 5α-reductase.
How could all this have been proved without 
a comparison with finasteride? This comparison 
would have addressed the best interest of pa-
tients and national health services but might also 
have threatened the commercial prospects of 
dutasteride, which its manufacturer hopes will 
replace the older but cheaper generic finasteride.
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To the Editor: Walsh dismisses the value of a 
reduction in moderately well-differentiated pros-
tate tumors (tumors with a Gleason score of 5 or 
6) in the REDUCE trial, suggesting that “many of 
the tumors were likely to have been clinically in-
significant.” A diagnosis of cancer, even indolent 
cancer, is important for the patient. Cancers ac-
quire major clinical significance if they drive 
radical intervention. And in the United States, 
92% of patients who have prostate cancer with a 
favorable risk receive radical intervention with its 
attendant complications and effects on quality of 
life.1 Even patients who elect the approach of ac-
tive surveillance acquire the “survivor” label and 
must deal with the psychological effects of a can-
cer diagnosis, repeated biopsies, and anxiety about 
the natural history of their cancer.2,3
Modeling of data from the Prostate Cancer 
Prevention Trial has suggested that the rate of 
both high-grade and low-grade cancers is reduced 
by treatment with a 5α-reductase inhibitor.4 
Whether one accepts this or not, the REDUCE 
study showed that dutasteride therapy, when used 
as a prevention strategy, will reduce overdiagno-
sis and hence overtreatment. This is of real value 
to patients.
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The authors reply: We agree with Kiemeney 
and Bosland that the results of the REDUCE trial 
cannot be directly translated to a clinical situa-
tion in which biopsies are performed only “for 
cause” and that the near elimination of high-
grade tumors in the placebo group during years 
3 and 4 may have been due to the fact that proto-
col-mandated biopsies were performed during 
years 1 and 2. Dutasteride may have inhibited the 
growth of low-grade and some high-grade tumors 
during years 1 and 2; hence, more remained to be 
detected during years 3 and 4. The rates of pros-
tate cancer in the placebo group exceeded general 
estimates, as expected, since a population that 
was at increased risk for prostate cancer (on the 
basis of PSA levels) was selected for evaluation.
Schröder and Roobol ask whether dutasteride 
can help avoid biopsies among men who do not 
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have prostate cancer. A large proportion of the 
negative biopsies in the REDUCE trial were 
protocol-mandated biopsies; in clinical practice, 
dutasteride should result in the need for fewer 
biopsies because it suppresses PSA production 
from benign tissue (and indolent prostate can-
cers), as seen in two previous studies.1,2 Data 
from the REDUCE trial showed that although 
rising PSA levels were a poor predictor of overall 
cancer and of high-grade cancer in the placebo 
group (perhaps since many placebo-treated men 
had rising PSA levels as a result of benign pros-
tatic hyperplasia), rising PSA levels were a strong 
predictor of tumors with Gleason scores of 7 to 
10 in the dutasteride group. The effect of dutas-
teride on the usefulness of PSA level for the diag-
nosis of prostate cancer would be the subject of 
a separate article.
Garattini and Bertele’ question why placebo 
(rather than finasteride) was chosen for compari-
son with dutasteride and whether the data from 
the REDUCE trial can help determine whether 
inhibition of both isoforms of 5α-reductase by 
dutasteride is superior to the inhibition of only 
one isoform by finasteride (as studied in the Pros-
tate Cancer Prevention Trial). Finasteride was not 
used in the REDUCE trial for three main reasons: 
finasteride is not an approved therapy for reduc-
ing the risk of prostate cancer, the REDUCE 
trial was initiated before the results of the Pros-
tate Cancer Prevention Trial were reported, and 
the reduction in the risk of prostate cancer with 
finasteride has never been tested in the popula-
tion studied in the REDUCE trial (men with ele-
vated PSA levels). Increased type 1 5α-reductase 
in prostate tumors, especially in high-grade tu-
mors, provides a biologically based rationale for 
the use of a dual inhibitor of 5α-reductase to 
achieve a reduction in the risk of prostate can-
cer3; however, the REDUCE trial was not designed 
to test this hypothesis directly. In a prespecified 
analysis of data from the REDUCE trial in which 
baseline predictors of prostate cancer and post-
baseline prostate volume at the time of biopsy 
were incorporated into the model (see the Sup-
plementary Appendix, available with the full text 
of the article at NEJM.org), the odds ratio for 
prostate cancer, detected on biopsy, with dutas-
teride as compared with placebo was 0.60 for all 
tumors (95% confidence interval [CI], 0.52 to 
0.68; P<0.001) and 0.62 for tumors with Gleason 
scores of 7 to 10 (95% CI, 0.49 to 0.79; P = 0.001).
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The editorialist replies: Garattini and Bertele’ 
argue that a direct comparison is necessary to 
determine whether dutasteride is equivalent to 
finasteride. I believe that such a study is unlikely 
to show any difference, because inhibition of the 
type 1 5α-reductase isoform does not appear to 
provide significant additional benefit. The relative 
reduction in the risk of a positive biopsy with ei-
ther agent is 23 to 25%, and among men who 
underwent random biopsies without a cause, there 
was neither a decrease nor an increase in the risk 
of prostate tumors with Gleason scores of 7 to 10.
Klotz misunderstands the clinical implications 
of the study. All the participants underwent ran-
dom biopsies. However, dutasteride reduced the 
risk of cancer only in men who would never have 
known that they had cancer and who would not 
have received treatment because in a clinical set-
ting they would never have undergone a biopsy. 
These were men with one or two previous nega-
tive biopsies who had been screened for more 
than 2 to 4 years and had no clinical indication 
for a biopsy. In contrast, among men with an 
indication for a biopsy (abnormal digital rectal 
examination or PSA level corrected for the effect 
of the drug), treatment with dutasteride failed to 
decrease the risk of cancer. Because treatment 
with dutasteride produces a marked reduction in 
PSA levels, men may be lulled into a false sense 
of security. They will interpret this reduction as 
they understand the effect of statins in lowering 
cholesterol (“My PSA is down by 50%; now I don’t 
have to worry about prostate cancer”) without 
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understanding that the decrease in PSA level is 
only the result of shrinkage of benign prostatic 
tissue. For this reason, dutasteride may delay the 
diagnosis of prostate cancer until a patient has 
high-grade disease that may be difficult to cure. 
As was concluded in another publication, “in 
clinical practice taking dutasteride would prob-
ably decrease the number of prostate biopsies 
and subsequent radiation treatments and prosta-
tectomies, but it might also increase the number 
of deaths from the disease.”1 Rather than advising 
the use of a drug that could be dangerous and 
costs $1,500 per year, if Dr. Klotz wishes to reduce 
the overdiagnosis and overtreatment of prostate 
cancer, why not simply discourage PSA testing?
Patrick C. Walsh, M.D.
Johns Hopkins Hospital  
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Ultrasound-Guided Internal Jugular Vein Cannulation
To the Editor: We wish that Ortega et al. (April 
22 issue)1 had demonstrated the use of the needle-
guide technique in their video of internal jugular 
vein cannulation. As noted in the video, it can be 
difficult to determine the location of the tip of 
the needle, which may be either in front of or 
behind the narrow cross-sectional plane of the 
ultrasound image. With the use of a needle guide, 
the operator can direct the needle tip such that it 
intersects the middle of the image on the screen 
at the depth prescribed by the guide. This tech-
nique has been shown to be superior to the free-
hand technique in successfully cannulating the 
internal jugular vein.2
We believe that the use of ultrasonography 
without a needle guide may give the operator a 
false sense of security, especially if the person 
doing the procedure lacks experience. Although 
imaging alone may help to identify the target 
vein, a needle guide allows for direct, real-time 
visualization of vessel puncture.
David Maslove, M.D. 
Frederick Mihm, M.D.
Stanford University Medical Center 
Stanford, CA 
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To the Editor: In their video, Ortega et al. failed 
to mention the use of the micropuncture tech-
nique for additional safety. A micropuncture 
needle is a very small, 22-gauge needle that can 
enter the jugular vein with little discomfort to 
the patient. Accidental puncture of the carotid 
artery with this small needle generally does not 
lead to major bleeding. The micropuncture tech-
nique is particularly helpful in children, in pa-
tients taking an anticoagulant, and in situations 
requiring immediate access. Unintentional pene-
tration of the posterior wall of the internal jugular 
vein during placement of a central catheter oc-
curs frequently, despite the use of ultrasound 
guidance.1 Use of the micropuncture needle can 
help to prevent the creation of a large posterior 
hole in the vein, thus reducing the likelihood of 
bleeding. In the cardiac catheterization labora-
tory at our institution, my colleagues and I re-
cently switched to the exclusive use of the micro-
puncture technique to obtain any vascular access. 
We believe that use of this technique should be-
come the standard of care in clinical practice.
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The Authors Reply: Despite the 18-minute du-
ration of our video, the multitude of techniques 
and approaches that can be used for internal 
jugular vein cannulation made it necessary for us 
to carefully decide which points to include and 
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